Capricor Therapeutics (CAPR) has provided an update.
The Company has recently shared a presentation on the progress of its CAP-1002 treatment for Duchenne muscular dystrophy during a call and webcast. This update, while informative, is not intended for regulatory filing purposes or to be considered as part of formal financial disclosures.
For detailed information about CAPR stock, go to TipRanks’ Stock Analysis page.
